C12Y 301/02022
Palmitoyl-protein hydrolase
Official title: Palmitoyl-protein hydrolase (3.1.2.22)
C12Y301/02022 (Palmitoyl-protein hydrolase) appears on 9 US grants and 18 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 18
- Assignees
- 7
- Inventors
- 20
- Latest grant
- 25 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 2 |
| 2021 | 1 | 2 |
| 2022 | 3 | 2 |
| 2023 | 0 | 2 |
| 2024 | 2 | 1 |
| 2025 | 1 | 3 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Optimized CLN1 genes and expression cassettes and their use25 Mar 2025US 12,257,322 B2The University of North Carolina at Chapel Hill
- Modified mammalian cells24 Sep 2024US 12,098,365 B2Genentech, Inc.
- Disulfide bond stabilized polypeptide compositions and methods of use20 Aug 2024US 12,064,485 B2Amicus Therapeutics, Inc.
- Optimized CLN1 genes and expression cassettes and their use22 Nov 2022US 11,504,435 B2The University of North Carolina at Chapel Hill
- Gene therapy constructs and methods of use8 Nov 2022US 11,491,243 B2Amicus Therapeutics, Inc.
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
- Modified mammalian cells9 Apr 2026US 2026/0098254 A1Genentech, Inc.
- Optimized cln1 genes and expression cassettes and their use19 Mar 2026US 2026/0077064 A1The University of North Carolina at Chapel Hill
- Adeno-Associated Virus Delivery of CLN1 Polynucleotide18 Dec 2025US 2025/0382593 A1Research Institute At Nationwide Children's Hospital
- Disulfide Bond Stabilized Polypeptide Compositions And Methods Of Use31 Jul 2025US 2025/0242057 A1Amicus Therapeutics, Inc.
Most cited
By later US patents
- Anti-human transferrin receptor antibody permeating blood-brain barrier5US 11,248,045 B2JCR Pharmaceuticals Co., Ltd. · 2022
- Modified diatoms for biofuel production4US 10,087,453 B2Cellectis · 2018
- Gene therapy constructs and methods of use3US 10,874,750 B2Amicus Therapeutics, Inc. · 2020
- Gene therapy constructs and methods of use2US 11,491,243 B2Amicus Therapeutics, Inc. · 2022